dexotc

Phase 2Small molecule

SSieff Medical Center

dexotc is one of 10 small molecule programs targeting Otitis Externa. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Otitis ExternaActive, not recruiting

Otitis ExternaPhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Otitis Externa

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—2

Decadron

AAspen Global Incorporated

Levaquin

Cipro

1 5

Voltaren

CCerimon Pharmaceuticals

Phase 2

1 6

Ciprodex

PPar Pharmaceutical, Inc.

Phase 3

3 7

DF277

SSalvat

Phase 3

1 8

DF289

SSalvat

Phase 3

1 9

OTO-201

OOtonomy, Inc.

Phase 2

1 10

dexotc

SSieff Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Otitis Externa1 trial

Topical Voltaren in Otitis Externa

Terminated·SSieff Medical Center·Phase 2·NCT00523120·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dexotc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dexotc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dexotc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sieff Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSieff Medical Center

dexotc

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Otitis Externa1 trial

References

Drug Info

Quick Facts

Related News